Clinical Trial Detail

NCT ID NCT02267603
Title Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

Merkel cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.